Fundamental analysis · SEC EDGAR · TTM through 28/03/2026

Fundamental analysis of Henry Schein Inc

HSIC · Nasdaq · Healthcare

Fundamental quality

DEMANDING

49

out of 100

Breakdown by area

I.GrowthEPS growth: -5% · Revenue growth: 1.8%
25
II.ProfitabilityNet margin: 3% · ROE: 12.1%
53
III.Financial healthNet debt/EBITDA: 1x · FCF: 3.3%
69

Source: SEC EDGAR · TTM through 28/03/2026

The score combines growth, profitability and financial strength. Here its financial strength weighs in its favor, while its growth drags it down the most.

Strengths

  • Low leverage (net debt of 1× EBITDA).

Risks and weaknesses

  • Thin margins (net margin of 3%).
  • Weak revenue growth (1.8% annualized).
  • Declining earnings per share (-5% annualized).

Historical evolution

YearRevenueNet incomeFree cash flowNet debt
202112,401631631
202212,647538506
202312,339416353
202412,673390700
202513,184398573

Between 2021 and 2025, revenue went from $12,401M to $13,184M (+6%) and net income went from $631M to $398M (-37%).

Annual figures in millions of U.S. dollars ($M) per SEC filings. Net debt is total debt minus cash.

Frequently asked questions

Is Henry Schein Inc a profitable company?

Henry Schein Inc is profitable, with a net margin of 3%, though a thin one.

Does Henry Schein Inc have a lot of debt?

Not particularly. Its net debt is 1 times its EBITDA, a low level.

Is Henry Schein Inc growing?

Its revenue has grown 1.8% annualized in recent years.

Does Henry Schein Inc generate cash?

Yes. It converts about 3.3% of its revenue into free cash flow.

The thresholds are general and the system doesn't judge qualitative factors. See the full methodology and use this analysis as a first filter, never as a final decision.

Is Henry Schein Inc cheap or expensive?

That depends on the current price. Look it up, enter it in the tool and get the full valuation verdict (P/E against its sector).

Compute the valuation →
Advertising

Where to buy Henry Schein Inc?

Brokers you can use to invest in U.S. and European stocks.

Compare the brokers →
Was this page helpful?